Quentin Hill: Collaborative Progress in Immune Thrombocytopenia Drug Development
Quentin Hill, Consultant Haematologist at Leeds Teaching Hospitals NHS Trust, shared Caroline Voltz-Girolt‘s post on LinkedIn, adding:
“In 2014, the EMA published guidelines for the development of medicinal products intended for treatment of chronic ITP.
The workshop below is part of a workstream that will result in an update of those guidelines. Very grateful to the EMA for taking the perspectives of clinicians and expert patients into consideration, and looking forward to publication of this important update.
Thanks also to Caroline Voltz-Girolt for seamless organisation”
Caroline Voltz-Girolt, Senior Scientific Officer in Office of Advanced Therapies and Haemato-Oncology at European Medicines Agency, shared a post on LinkedIn:
“On 30 June 2026, EMA organised a workshop on the challenges in drug development, regulation and clinical practice in immune thrombocytopenia.
We had highly insightful discussions on this topic. A sincere thank you to all the speakers for their comprehensive presentations, thoughtful perspectives, and excellent contributions to the discussion.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 06:46Neeraj Songara: From Donated Blood to Engineered Therapeutics
-
Sep 20, 2026, 06:24Louise St. Germain Bannon: Improving Awareness and Care for Women Across the Lifespan
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems